Eli Lilly CEO: Covid antibody treatment will help reduce hospitalizations

The U.S. Food and Drug Administration on Monday authorized emergency use of Eli Lilly’s experimental Covid-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions. Eli Lilly CEO David Ricks joins "Squawk Box" to discuss the efficacy of the treatment and some of the challenges surrounding how the drug is administered.